Polarean’s Dr. Bastiaan Driehuys Recognized for Breakthroughs in Xenon MRI

PUBLISHED: 21 May 2025 @ 18:23 | Comments (0) | More info about Fiona Craig

Polarean Imaging (LSE:POLX) announced that its Chief Scientific Officer, Dr. Bastiaan Driehuys, has been honored with the 2025 American Thoracic Society Respiratory Health Award. This prestigious accolade acknowledges Dr. Driehuys’ groundbreaking work in developing Xenon MRI technology, which has significantly advanced pulmonary imaging. His innovations have enabled earlier detection and more precise treatment planning for respiratory diseases, improving patient care worldwide.

About Polarean Imaging

Polarean Imaging specializes in cutting-edge medical imaging technologies designed to transform lung health diagnostics. The company developed XENOVIEW®, the first FDA-approved inhaled contrast agent utilizing hyperpolarized Xenon gas for MRI scans, providing unparalleled visualization of lung function. Polarean is dedicated to addressing critical unmet needs in respiratory medicine through its pioneering imaging solutions.

Average Trading Volume: 2,574,230 shares
Technical Sentiment Signal: Sell
Market Capitalization: £14.48 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.